A contemporary view of the definition and diagnosis of osteoporosis in children and adolescents

Ward, Leanne M; Weber, David R; Munns, Craig F; Högler, Wolfgang; Zemel, Babette S

DOI:

[10.1210/clinem/dgz294](https://doi.org/10.1210/clinem/dgz294)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ward, LM, Weber, DR, Munns, CF, Högler, W & Zemel, BS 2019, 'A contemporary view of the definition and diagnosis of osteoporosis in children and adolescents', *Journal of Clinical Endocrinology and Metabolism*.
<https://doi.org/10.1210/clinem/dgz294>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is a pre-copyedited, author-produced version of an article accepted for publication in The Journal of Clinical Endocrinology & Metabolism following peer review. The version of record Leanne M Ward, David R Weber, Craig F Munns, Wolfgang Högler, Babette S Zemel, A Contemporary View of the Definition and Diagnosis of Osteoporosis in Children and Adolescents, The Journal of Clinical Endocrinology & Metabolism, is available online at: <https://doi.org/10.1210/clinem/dgz294>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

**A Contemporary View of the Definition and Diagnosis of Osteoporosis
in Children and Adolescents**

Leanne M. Ward¹, David R. Weber², Craig F. Munns³, Wolfgang Högler⁴, and Babette S. Zemel⁵

¹Departments of Pediatrics and Surgery, University of Ottawa, and the Children's Hospital of Eastern Ontario, Division of Endocrinology and Metabolism, Ottawa, Ontario, Canada

²Golisano Children's Hospital, University of Rochester, New York, USA

³Department of Endocrinology, The Children's Hospital at Westmead, Westmead, Australia, and Discipline of Paediatrics & Child Health, University of Sydney, Australia

⁴Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria, and the Institute of Metabolism and Systems Research, University of Birmingham, United Kingdom

⁵Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, USA

Word Count:

Abstract: 245

Text: 3886

Corresponding Author:

Dr. Leanne Ward MD FRCPC

Research Chair in Pediatric Bone Health

Professor of Pediatrics, University of Ottawa

Medical Director, The CHEO Bone Health Clinic

Scientific Director, The Ottawa Pediatric Bone Health Research Group

Room 250H

Children's Hospital of Eastern Ontario Research Institute

401 Smyth Road
Ottawa, Ontario, Canada K1H 8L1
Email: Lward@cheo.on.ca

Running Title: Definition and diagnosis of pediatric osteoporosis

Key Words: osteoporosis, children, diagnosis, definition, fractures, long bone, vertebral, bone mineral density, osteogenesis imperfecta, risk factors, DXA

Disclosures: LMW has participated in clinical trials with and received research funding from Novartis, Amgen, and Ultragenyx. CFM has received research funding from Ultragenyx, Kyowa Kirin, Novartis, Amgen and Alexion, and is a consultant for Kyowa Kirin and Alexion; WH has participated in clinical trials with Ultragenyx and Alexion, and has received research funding from Kyowa Kirin, Ultragenyx, Alexion, Internis and Nutricia. DRW and BSZ declare that they have no conflicts of interest to disclose.

Precis:

We propose a new approach to the definition and diagnosis of osteoporosis in children, one that includes BMD, but also fracture characteristics, risk factors for fractures, and the clinical context.

Abstract

The last two decades have seen growing recognition of the need to appropriately identify and treat children with osteoporotic fractures. This focus stems from important advances in our understanding of the genetic basis of bone fragility, the natural history and predictors of fractures in chronic conditions, the use of bone-active medications in children, and the inclusion of bone health screening into clinical guidelines for high risk populations. Given the historic focus on bone densitometry in this setting, The International Society for Clinical Densitometry published revised criteria in 2013 to define osteoporosis in the young, oriented towards prevention of over-diagnosis given the high frequency of extremity fractures during the growing years. This definition has been successful in avoiding an inappropriate diagnosis of osteoporosis in healthy children who sustain long bone fractures during play. However, it's emphasis on the number of long bone fractures and a concomitant bone mineral density (BMD) threshold ≤ -2.0 , without consideration for long bone fracture characteristics (e.g. skeletal site, radiographic features) or the clinical context (e.g. known fracture risk in serious illnesses or physical-radiographic stigmata of osteoporosis), inappropriately misses clinically relevant bone fragility in some children. In this perspective, we propose a new approach to the definition and the diagnosis of osteoporosis in children, one that balances the role of BMD in the pediatric fracture assessment with other important clinical features, including fracture characteristics, the clinical context, and where appropriate, the need to define the underlying genetic etiology as far as possible.

Introduction

Recent years have witnessed a growing recognition of the need to identify and treat children with bone fragility. Given the historic focus on bone densitometry in the assessment of children with fractures, or at risk for bone fragility, the International Society for Clinical Densitometry (ISCD) held a series of Position Development Conferences to provide guidance for the use of dual-energy x-ray absorptiometry (DXA) in children, and to standardize approaches to define osteoporosis in the young. Much has changed in the field of pediatric bone health since the first ISCD Pediatric Positions were published in 2003 (1). Notable advances include the widespread availability of clinical genetic testing, a deeper understanding of the natural history and predictors of fractures in pediatric osteoporotic conditions (2-4), the development of targeted pharmacotherapy for rare diseases (5), more experience with the use of medications to treat pediatric osteoporosis (6), and the inclusion of bone health screening into clinical guidelines for chronic childhood diseases (7, 8).

As the diagnostic tools and treatments available have evolved, there is need for a better definition of osteoporosis in children, one that readily identifies those with underlying bone fragility. An optimal definition of osteoporosis should therefore: 1. Ensure that children with skeletal fragility are identified, appropriately evaluated for an underlying diagnosis, assessed for the likelihood of recovery without bone-specific therapy, and treated in a timely manner if warranted; and 2. Facilitate the development and implementation of individualized care plans that seek to prevent major osteoporotic fractures, provide pain relief, and foster mobility.

The intent of this perspective is to re-visit the definition of pediatric osteoporosis (9), and in so doing provide a conceptual framework for identifying and managing children with skeletal fragility.

The Current Definition of Pediatric Osteoporosis

Background

Fractures in childhood are common, with about half of children experiencing at least one fracture prior to adulthood (10, 11), and more than 20% of children with fractures having sustained a prior broken bone (12). Over the years, the ISCD Pediatric Positions Task Forces aimed for definitions of pediatric osteoporosis that would distinguish children with “...an intrinsic skeletal issue resulting in bone fragility”, from children who experience fracture as a result of typical childhood play and sport activities (9, 13).

Last updated in 2013, the ISCD recommendations on the diagnosis of osteoporosis in children (9) stated that the diagnosis should not be based upon densitometric criteria alone, but requires a clinically significant fracture history. The criteria for osteoporosis included the presence of a non-traumatic vertebral compression fracture (VF), without the need for BMD criteria. This appropriately recognized the pathological nature of low-trauma VF in children. In the absence of a VF, the diagnosis required the presence of both a clinically significant fracture history (≥ 2 long bone fractures by age 10 years, or ≥ 3 long bone fractures by 19 years), and a low age- and gender-matched BMD Z-score of ≤ -2.0 (with appropriate corrections for bone size). The definition additionally noted that a BMD Z-score of >2.0 in this context “does not preclude the possibility of skeletal fragility and increased fracture risk”.

Successes and Challenges

The ISCD definition of pediatric osteoporosis (9) is widely used to inform clinical practice, health care policy and institutional protocols. The definition has also been used to determine eligibility for investigator-initiated studies and health authority-regulated drug trials. This 2013 ISCD definition provides a reasonable safeguard against the over-diagnosis and unnecessary treatment of children who do not have true skeletal fragility. This is important, because the most widely used osteoporosis therapies in children (intravenous neridronate, pamidronate and zoledronic acid) should be used with caution.

On the other hand, the difficulty in defining low-energy trauma has been a major obstacle to identifying children with intrinsic skeletal fragility. When strictly applied, the 2013 ISCD definition results in the under-diagnosis and thereby under-treatment of children with congenital forms of bone fragility, and of children with secondary osteoporosis due to, for example, osteotoxic exposures such as glucocorticoids (GCs) or immobility. Specifically, waiting for a second (or third) long bone fracture, or for a low BMD by DXA following low-trauma fractures, unnecessarily delays initiation of treatment in a high-risk population where even a single fracture can be life-altering and lead to permanent disability. The following discussion aims to overcome these limitations.

An additional challenge in defining osteoporosis is the inclusion of a BMD Z-score threshold. BMD Z-scores vary by as much as two standard deviations for a given child depending on the reference database used to generate the Z-score. This finding has been described by three different groups using both Hologic- and Lunar-derived pediatric reference data (14-16); the largest of these reports generated BMD Z-scores

from all of the available pediatric reference data published in English as of 2015 (16). This variability in BMD Z-scores generated by different reference databases undermines the use of a Z-score cut-off as part of an international osteoporosis definition in children. Another concern is that children with bone fragility due to, for example, leukemia, neuromuscular disorders, and osteogenesis imperfecta (OI), can sustain osteoporotic fractures at BMD Z-scores > -2.0 (16-18), a point recognized in the 2013 ISCD report. However, the reference databases are highly co-linear. Consequently, the relationships between, for example, lumbar spine BMD Z-scores and VFs (i.e. odds for fracture) are similar regardless of the database used to generate the BMD Z-scores (16). This means that the lower the BMD Z-score generated by any reference database, the more likely a child is to sustain a pathological vertebral or long bone fracture (17). With this in mind, we propose to regard BMD Z-scores along a continuum that is directly correlated to bone strength, but without diagnostic cut-offs, since the precise location of the healthy mean and outer limits of normal on the continuum will vary, depending on the reference database used to generate the Z-scores.

A Contemporary View of Osteoporosis in Children - Integrating Fracture Characteristics and Clinical Context into the Diagnostic Approach

A more contemporary and nuanced diagnostic approach to pediatric osteoporosis emphasizes the child's risk of a fracture, fracture characteristics, and the clinical context, without a specific BMD Z-score requirement (17, 19, 20). Such an approach requires the clinician to understand the following aspects of their patient's profile: 1. the *a priori* risk of a fragility fracture, 2. the mechanism, location and radiographic features of the fracture, 3. the precise definition of a VF (considered pathognomonic of

osteoporosis in the low-trauma setting), 4. the clinical characteristics that support an underlying bone fragility condition, and 5. the family history and genotype, in those suspected of a heritable form. This approach has been stirred not only by the limitations of BMD thresholds to define osteoporosis in children, but by the recent explosion in our knowledge about the genetic basis of congenital bone fragility (19, 20), and the natural history of osteoporotic fractures in children with secondary causes.

The fracture characteristics and clinical contexts that support the need for a bone health evaluation, and that provide evidence for an osteoporosis diagnosis

Non-vertebral fractures

The overall risk of a fracture between birth and 16 years ranges from 42 to 64% for boys, and from 27 to 40% for girls (11). A consistent finding across all epidemiological studies is that the most frequent site of fracture is the forearm, which accounts for nearly half of all fractures (11, 17). Sixty-five percent of all long bone fractures in childhood involve the upper extremity, and 7 to 28% the lower extremity (11). The fracture rate during childhood is higher than during adult life, hypothesized to result from the constant lag during the growing years between the mechanical challenges that induce bone tissue strain (muscle forces and longitudinal growth), and the adaptive changes in bone structure that foster bone strength in response to tissue strain (21).

Recognizing that long bone fractures are extremely common in childhood, the ISCD 2013 Position Statement defined significant fracture history as ≥ 2 long bone fractures by age 10 years, or ≥ 3 long bone fractures by age 19 years (9). We consider these numbers reasonable for a child with absent physical stigmata or risk factors suggestive

of underlying bone fragility. However, additional factors should be considered in the decision to initiate a comprehensive bone health evaluation and/or to diagnose a child with osteoporosis: the location and radiographic features of the long bone fracture, and the clinical context in which the child presents with fractures.

The importance of a long bone fracture's location cannot be underestimated. Even a single, low-trauma long bone fracture can represent a major osteoporotic event in children with first presentations of OI (20), and in children with risk factors such as Duchenne muscular dystrophy (DMD) (2). Lower extremity fractures tend to have the greatest impact on daily life because of the adverse effect on mobility. Low-trauma femur fractures are particularly concerning, but even a single tibia or humerus fracture can represent an osteoporotic event in those at risk, and should prompt careful dissection of the injury's mechanism. Forearm fractures are so common in children, that typically recurrent fractures at this site are needed to trigger a comprehensive bone health evaluation, unless there are known risk factors (such as DMD), or classical stigmata of OI (such as blue sclera). Comminuted fractures and those with atypical displacement are also significant regardless of long bone site, especially when they occur in the absence of trauma.

Flat bone fractures (scapula, sternum, skull and rib) usually result from significant trauma, and raise red flags when they do not. Rib and scapula "pseudofractures", otherwise known as "looser zones", are typical features of rickets and osteomalacia, and should prompt testing for a disorder of mineral ion metabolism. Given the completely disparate treatment approaches, ruling out rickets is the first step in the medical evaluation of any low-trauma fracture.

211 Importantly, the possibility of non-accidental trauma must be considered in any child,
212 regardless of the fracture location, particularly if the fracture occurs prior to two years of
213 age, if there are delays in seeking medical attention, if the clinical evaluation reveals
214 unexplained bruising or other signs of injury such as retinal hemorrhages, if there are
215 multiple fractures in various stages of healing, or if the reported mechanism of injury
216 does not correlate with the fracture type.

217 Trans-iliac bone biopsies provided discrete clues about novel forms of OI prior to gene
218 discovery in the past, such as in OI type VI, ultimately shown to be due to mutations in
219 *SERPINF1* (22). This technique will continue to be useful in pursuing novel diagnoses
220 going forward, by providing the impetus for more advanced genetic scrutiny such as
221 whole exome sequencing.

222 Just as the clinical context is paramount in orienting the clinician to the possibility of
223 non-accidental trauma, the context also orients the clinician to the likelihood of an
224 osteoporotic fracture. For example, in boys with GC-treated DMD, VFs were frequent in
225 the years following a single low-trauma long bone fracture (2), providing proof of
226 principle that the initial long bone fracture, was the first osteoporotic event. For a child
227 with physical stigmata of congenital bone fragility such as blue sclera, joint
228 hypermobility, skin laxity, impaired growth, scoliosis, limb deformity, tooth abnormalities,
229 easy bruising, dysmorphism, multiple Wormian bones, and/or a positive family history,
230 the threshold for initiating a bone health evaluation is lower than in the absence of such
231 signs. In children with stigmata which together suggest the possibility of OI or an OI-like
232 disorder, the bone fragility assessment may be undertaken even before presentation

with fractures, to pursue a monogenic form of osteoporosis (23), and to detect VFs that may be present in the asymptomatic phase.

Vertebral fractures

We support the ongoing use of the 2013 ISCD Position Statement that ≥ 1 VF, defined as $>20\%$ loss of vertebral height ratio according to the Genant semi-quantitative method (24), is consistent with a diagnosis of osteoporosis. This was further supported in the 2019 ISCD Position Statement (25). Pediatric VFs are extremely rare in the absence of trauma (10), but occur in 75% of children with OI due to *COL1A1* haploinsufficiency mutations (26), in one third of children with leukemia (3), in $>50\%$ of boys with GC-treated DMD (27), and in 16% of otherwise healthy fracture-prone children (28). In a study of children with leukemia, the relationship between Genant-defined VFs at diagnosis and subsequent new vertebral and long bone fractures provided validity for the use of the Genant method to define VFs in children (3). The fact that VFs can be a presenting sign of serious systemic diseases like leukemia and inflammatory disorders underscores the importance of the 2013 ISCD recommendation that even a single VF can be a manifestation of osteoporosis in children (29-31).

Definition of low-trauma

Low-trauma has been defined in numerous ways. The 2013 ISCD criteria defined low-trauma fractures as those occurring outside of motor vehicle accidents, or falling from 10 feet (3 meters) or less. With respect to falls in the chronic illness setting, a more conservative definition has been used - falling from a standing height or less, at no more than walking speed (3). This latter definition holds validity in the chronic illness setting,

since VFs predicted incident low-trauma long bone fractures defined in this way (3). At the same time, it is important to recognize that children with high-trauma fractures may also have a bone fragility condition, a reminder that screening for telltale signs of osteoporosis even at the time of first presentation for fracture management, such as blue sclerae or dentinogenesis imperfecta, is warranted.

Synthesizing fracture characteristics and the clinical context into a contemporary approach to the diagnosis of osteoporosis in children

Figure 1 encourages the clinician to consider the relationship between the severity of the child's fracture phenotype, and the magnitude of supporting clinical features and risk factors that are needed to trigger a comprehensive bone health evaluation. This figure conveys the balance of factors in favour or against a diagnosis of osteoporosis based on clinical information. In **Figure 2**, we propose a comprehensive diagnostic pathway that expands on the principles in **Figure 1**, based on current knowledge about the key elements of a pediatric bone health evaluation. The concepts in **Figures 1** and **2** apply to infants, toddlers, children and adolescents.

In **Figure 2**, we recommend that children undergo a work-up to explore a disorder of mineral metabolism (e.g. rickets), and serious underlying acute (e.g. leukemia) or chronic (e.g. inflammatory bowel disease, juvenile arthritis) illness. **Figure 2** provides a general framework for this initial work-up, which should be tailored to the presenting symptoms and ensure use of pediatric reference data for biochemical testing. If negative, the next step is to undertake a formal osteoporosis evaluation, including DXA-based BMD parameters and a lateral thoracolumbar spine radiograph. Given the importance of vertebral fracture identification in the pediatric osteoporosis work-up, an

278 ISCD Pediatric Task Force recently reviewed and subsequently endorsed the use of
279 DXA-based BMD for vertebral fracture assessment (VFA) in children, as updated in the
280 2019 ISCD Official Pediatric Position report (25). Occasionally, magnetic resonance
281 imaging is needed to clarify equivocal cases. Some children need more extensive
282 imaging than others, depending on the clinical context. For example, a hand x-ray (for
283 bone age and to rule out rickets) and DXA-based VFA or lateral spine x-ray are usually
284 sufficient in children with secondary osteoporosis. Children with suspected primary
285 osteoporosis typically undergo additional x-rays, to query Wormian bones of the skull
286 and skeletal deformity. In children who do not have positive clinical/radiographic/genetic
287 characteristics to support an osteoporosis diagnosis, we propose it is reasonable to
288 then follow the 2013 ISCD definition of osteoporosis regarding the requisite number of
289 long bone fractures (minus the need for specific BMD criteria, as discussed in the next
290 section). In such cases, we recommend monitoring the child's ability to return to normal
291 physical activities without further fractures, and the child's rate of bone mineral accrual
292 (32). For example, a child without obvious stigmata of OI but who continues to sustain
293 fractures or fails to accrue bone at a normal rate may tip the balance to more
294 aggressive testing (such as whole exome studies).

295 Bone turnover markers (BTM) are not part of the standard work-up for childhood
296 osteoporosis. BTM are highly correlated with growth velocity, and therefore difficult to
297 interpret. Abnormal BTM (using appropriate reference data) may provide diagnostic
298 clues in some cases. Bone resorption markers may be high pre-bisphosphonate therapy
299 in children with OI (33), and correlate with an elevated trabecular bone formation rate on
300 trans-iliac biopsies (34). Reductions in bone resorption markers, and low trabecular

bone formation, have been observed on chronic glucocorticoid therapy (35, 36), and in juvenile osteoporosis due to mutations in *LRP5* (37, 38).

The Role of BMD in the Diagnostic Pathway

This paradigm raises the fundamental question - what is the role of DXA-based BMD in the assessment of pediatric fractures? While a low BMD raises the index of suspicion for an osteoporotic fracture, it is not diagnostic, since BMD can be low simply due to a size artefact (as in short stature), or in non-osteoporotic conditions with fractures such as rickets and hypophosphatasia. Furthermore, BMD can be normal in children with fractures due to both primary and secondary osteoporosis. In rare cases, fragility fractures are a sign of a sclerosing bone disorder, a diagnosis that should be evident on plain radiographs but which can be confirmed by a high BMD Z-score in more subtle cases. Overall, BMD is only one of many jigsaw pieces that orient the clinician as to whether there are sufficient clinical features to warrant expanded diagnostic testing, such as genetic profiling for primary osteoporosis, or chronic illness work-ups for conditions such as neuromuscular disorders (e.g. congenital myopathies, DMD), inflammatory states (e.g. Crohn's disease and rheumatic conditions), or nutritional compromise (e.g. celiac disease). The main purpose of BMD in the childhood fracture setting, then, is to provide additional supporting evidence to justify a more comprehensive osteoporosis work-up in equivocal cases. In uncertain cases, the BMD trajectory can be useful, with a loss of ≥ 0.5 SD considered to be clinically significant, providing a threshold to trigger more comprehensive bone health testing (7).

A number of considerations must be taken into account when acquiring and interpreting DXA scans in children. The choice of skeletal site should be informed by individual

patient characteristics, and local access to appropriate reference data is paramount. Lumbar spine (L1-L4) and whole body (total body less head) BMD have been the most widely used parameters in children to date, and associate with fracture risk (3, 39). In 2019, the ISCD recommendations were updated to additionally endorse DXA-based BMD at the distal forearm, proximal hip, and lateral distal femur in children who need additional information for clinical decision-making, or in whom spine or whole body DXA scans cannot be obtained (e.g. indwelling hardware) (25). Areal BMD by DXA is subject to size artifact; therefore, children with short stature and/or pubertal delay will have artificially low BMD Z-scores relative to healthy reference data. To better estimate BMD in short children, size-adjustment techniques have been developed including bone mineral apparent density (40, 41), and height Z-score-adjusted BMD Z-scores (42).

Peripheral quantitative computed tomography at the radius and tibia provide valuable information that cannot be obtained by DXA, including bone and muscle geometry, as well as “true” (volumetric) cortical and trabecular BMD. The 2013 ISCD Official Pediatric Positions noted that optimal measurement sites and scanning protocols have not been established for children; furthermore, reference data are limited. As such, this technique is presently restricted to highly specialized centres and research studies (43).

Recognition that the Diagnosis of Osteoporosis Does Not Always Signal the Need for Treatment

The diagnosis of osteoporosis in children does not necessarily signal the need to treat. Unlike adults, the pediatric skeleton is driven to undergo bone mass restitution and to reshape previously fractured vertebral bodies. Vertebral body reshaping is due to skeletal modeling arising from the vertebral growth plates (i.e. vertebral “catch-up

growth”), provided the child’s risk factors are transient and there remains sufficient residual growth potential. These principles are best exemplified in children with leukemia; most are diagnosed at a young age (on average between 4-6 years of age) and the bone health threat is usually transient (> 90% cure rate after 2-4 years of chemotherapy) (44). In childhood leukemia, nearly 80% of those with VFs undergo complete vertebral body reshaping without bone-specific treatment by six years following diagnosis (3).

At the opposite end of the spectrum, long bone and VF rates are so high in GC-treated DMD, and risk factors are so aggressive and persistent, that medication-unassisted vertebral body reshaping and improvements in bone mineral accrual have not been reported. These observations shaped recent recommendation to monitor for signs of osteoporosis with annual spine radiographs starting at the time of GC initiation in DMD, and to start osteoporosis intervention at the first sign of a single low-trauma long bone or VF (7).

These two contrasting clinical scenarios underscore the importance of assessing whether the child with osteoporotic fractures needs osteoporosis therapy, recognizing that younger age, transient risk factors and less severe vertebral collapse are key determinants of recovery without the need for intervention (3).

Peering into the Next Decade

In this perspective, we propose an expanded diagnostic approach to children with fractures, one that continues to respect the need to avoid over-diagnosis in healthy children. At the same time, our approach safeguards against missed diagnoses in

milder or first-fracture cases of osteoporosis. As such, we are moving away from a requisite number of long bone fractures and a low BMD, to an approach that incorporates long bone fracture features, the clinical context including fracture risk, and signs of a genetic disorder.

With pediatric bone mineral accrual Z-score equations now available (32), researchers over the next decade are well-poised to assess the relationship between bone mineral accrual rates and the osteoporosis diagnostic yield. In this context, it will be important to ensure that BMD/BMC Z-score trajectories are determined using the same DXA machine and software version, and that if changes in either are made over time, appropriate machine cross-calibration factors are applied. For disease groups at very high fracture risk such as DMD, bone mineral accrual rates may aid risk stratification for enrolment in osteoporosis prevention trials. Furthermore, recognition that VF detection is an important part of the bone health evaluation has spurred interest in the use of DXA-based VF assessment as a diagnostic tool, in order to minimize radiation exposure. In addition, the diagnostic validity of novel imaging technology such as high resolution peripheral quantitative CT needs to be established.

The most pressing unmet need going forward is to understand the etiology and mechanisms that lead to fragility fractures in otherwise healthy children with an absent family history, lack of typical stigmata of OI and negative genetic testing, as reported in 72% of such patients in a recent study (19). These children remind the global pediatric community that the door remains open to additional discovery of monogenic and polygenic bone strength determinants, which in turn will shed more light on the pathobiology and diagnosis of osteoporotic fractures in children and adolescents. As

part of this mission, national health authorities, independent of socioeconomic status, should promote access to specialized centres for rare diseases that includes genetic testing, so that no child goes without the essentials of osteoporosis management in the future.

Acknowledgments: Dr. Ward is supported by a Research Chair Award from the University of Ottawa, and The CHEO Departments of Pediatrics and Surgery. Dr. Weber is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant number K23 DK114477

References

1. **Writing Group of the ISCD Position Development Conference.** 2004
Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin
Densitom 7:17-26
2. **Ma J, McMillan HJ, Karaguzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM** 2017 The time
to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Osteoporos Int 28:597-608
3. **Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, Shenouda N, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis V, Israels S, Grant RM, Fernandez CV, Dix DB, Cummings EA, Couch R, Cairney E, Barr R, Abish S, Atkinson SA, Hay J, Rauch F, Moher D, Siminoski K, Halton J** 2018 Bone Morbidity and Recovery in Children With
Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study.
J Bone Miner Res 33:1435-1443
4. **LeBlanc CM, Ma J, Taljaard M, Roth J, Scuccimarri R, Miettunen P, Lang B, Huber AM, Houghton K, Jaremko JL, Ho J, Shenouda N, Matzinger MA, Lentle B, Stein R, Sbrocchi AM, Oen K, Rodd C, Jurencak R, Cummings EA, Couch R, Cabral DA, Atkinson S, Alos N, Rauch F, Siminoski K, Ward LM**
2015 Incident Vertebral Fractures and Risk Factors in the First Three Years
Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic
Disorders. J Bone Miner Res 30:1667-1675

5. **Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millan JL, Skrinar AM, Crine P, Landy H** 2012 Enzyme-replacement therapy in life-threatening hypophosphatasia. *N Engl J Med* 366:904-913
6. **Nasomyont N, Hornung LN, Gordon CM, Wasserman H** 2019 Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. *Bone* 121:60-67
7. **Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM** 2018 Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol* 17:347-361
8. **Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG** 2017 Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 102:3869-3903
9. **Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N** 2014 Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD 2013 Pediatric Official Positions. *J Clin Densitom* 17:275-280

- 457 10. **Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP** 2004
458 Epidemiology of childhood fractures in Britain: a study using the general practice
459 research database. *J Bone Miner Res* 19:1976-1981
- 460 11. **Clark EM** 2014 The epidemiology of fractures in otherwise healthy children. *Curr*
461 *Osteoporos Rep* 12:272-278
- 462 12. **Mayranpaa MK, Makitie O, Kallio PE** 2010 Decreasing incidence and changing
463 pattern of childhood fractures: A population-based study. *J Bone Miner Res*
464 25:2752-2759
- 465 13. **Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB,**
466 **Rauch F** 2008 Official Positions of the International Society for Clinical
467 Densitometry and executive summary of the 2007 ISCD Pediatric Position
468 Development Conference. *J Clin Densitom* 11:6-21
- 469 14. **Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI** 1999
470 Discrepancies in pediatric bone mineral density reference data: potential for
471 misdiagnosis of osteopenia. *The Journal of pediatrics* 135:182-188
- 472 15. **Kocks J, Ward K, Mughal Z, Moncayo R, Adams J, Hogler W** 2010 Z-score
473 comparability of bone mineral density reference databases for children. *The*
474 *Journal of clinical endocrinology and metabolism* 95:4652-4659
- 475 16. **Ma J, Siminoski K, Alos N, Halton J, Ho J, Lentle B, Matzinger M, Shenouda**
476 **N, Atkinson S, Barr R, Cabral DA, Couch R, Cummings EA, Fernandez CV,**
477 **Grant RM, Rodd C, Sbrocchi AM, Scharke M, Rauch F, Ward LM** 2015 The
478 choice of normative pediatric reference database changes spine bone mineral

density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. J Clin Endocrinol Metab 100:1018-1027

17. **Fiscaletti M, Coorey CP, Biggin A, Briody J, Little DG, Schindeler A, Munns CF** 2018 Diagnosis of Recurrent Fracture in a Pediatric Cohort. Calcif Tissue Int 103:529-539

18. **Henderson RC, Berglund LM, May R, Zemel BS, Grossberg RI, Johnson J, Plotkin H, Stevenson RD, Szalay E, Wong B, Kecskemethy HH, Harcke HT** 2010 The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25:520-526

19. **Bardai G, Ward LM, Trejo P, Moffatt P, Glorieux FH, Rauch F** 2017 Molecular diagnosis in children with fractures but no extraskkeletal signs of osteogenesis imperfecta. Osteoporos Int 28:2095-2101

20. **Bardai G, Moffatt P, Glorieux FH, Rauch F** 2016 DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos Int 27:3607-3613

21. **Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R** 2004 The 'muscle-bone unit' during the pubertal growth spurt. Bone 34:771-775

22. **Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B** 2011 Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res 26:2798-2803

- 502 23. **Makitie RE, Costantini A, Kampe A, Alm JJ, Makitie O** 2019 New Insights Into
503 Monogenic Causes of Osteoporosis. *Front Endocrinol (Lausanne)* 10:70
- 504 24. **Genant HK, Wu CY, van Kuijk C, Nevitt MC** 1993 Vertebral fracture
505 assessment using a semiquantitative technique. *J Bone Miner Res* 8:1137-1148
- 506 25. **Weber DR, Boyce A, Gordon C, Hogler W, Kecs kemethy HH, Misra M,**
507 **Swolin-Eide D, Tebben P, Ward LM, Wasserman H, Shuhart C, Zemel BS**
508 2019 The Utility of DXA Assessment at the Forearm, Proximal Femur, and
509 Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric
510 Population: The 2019 Official Pediatric Positions of the ISCD. *J Clin Densitom*
- 511 26. **Ben Amor IM, Roughley P, Glorieux FH, Rauch F** 2013 Skeletal clinical
512 characteristics of osteogenesis imperfecta caused by haploinsufficiency
513 mutations in COL1A1. *J Bone Miner Res* 28:2001-2007
- 514 27. **Singh A, Schaeffer EK, Reilly CW** 2016 Vertebral Fractures in Duchenne
515 Muscular Dystrophy Patients Managed With Deflazacort. *J Pediatr Orthop*
- 516 28. **Mayranpaa MK, Viljakainen HT, Toiviainen-Salo S, Kallio PE, Makitie O** 2012
517 Impaired bone health and asymptomatic vertebral compressions in fracture-
518 prone children: a case-control study. *J Bone Miner Res* 27:1413-1424
- 519 29. **Halton J, Gaboury I, Grant R, Alos N, Cummings EA, Matzinger M,**
520 **Shenouda N, Lentle B, Abish S, Atkinson S, Cairney E, Dix D, Israels S,**
521 **Stephure D, Wilson B, Hay J, Moher D, Rauch F, Siminoski K, Ward LM**
522 2009 Advanced vertebral fracture among newly diagnosed children with acute
523 lymphoblastic leukemia: results of the Canadian Steroid-Associated

Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 24:1326-1334

30. **Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS, Harbison M, Berdon W, Oberfield SE** 2000 Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab 85:2122-2126.
31. **Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure D, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM** 2010 Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 62:516-526
32. **Kelly A, Shults J, Mostoufi-Moab S, McCormack SE, Stallings VA, Schall JI, Kalkwarf HJ, Lappe JM, Gilsanz V, Oberfield SE, Shepherd JA, Winer KK, Leonard MB, Zemel BS** 2019 Pediatric Bone Mineral Accrual Z-Score Calculation Equations and Their Application in Childhood Disease. J Bone Miner Res 34:195-203
33. **Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH** 2003 Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986-992
34. **Rauch F, Travers R, Plotkin H, Glorieux FH** 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299

35. **Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM** 2012 The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. *Osteoporos Int* 23:2703-2711
36. **Ward LM, Rauch F, Matzinger MA, Benchimol EI, Boland M, Mack DR** 2010 Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. *Osteoporos Int* 21:331-337
37. **Hartikka H, Makitie O, Mannikko M, Doria AS, Daneman A, Cole WG, Alakokko L, Sochett EB** 2005 Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. *J Bone Miner Res* 20:783-789
38. **Fahiminiya S, Majewski J, Roughley P, Roschger P, Klaushofer K, Rauch F** 2013 Whole-exome sequencing reveals a heterozygous LRP5 mutation in a 6-year-old boy with vertebral compression fractures and low trabecular bone density. *Bone* 57:41-46
39. **Goulding A, Jones IE, Taylor RW, Manning PJ, Williams SM** 2000 More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures. *J Bone Miner Res* 15:2011-2018
40. **Crabtree NJ, Shaw NJ, Bishop NJ, Adams JE, Mughal MZ, Arundel P, Fewtrell MS, Ahmed SF, Treadgold LA, Hogler W, Bebbington NA, Ward KA** 2017 Amalgamated Reference Data for Size-Adjusted Bone Densitometry Measurements in 3598 Children and Young Adults-the ALPHABET Study. *J Bone Miner Res* 32:172-180

41. **Kindler JM, Lappe JM, Gilsanz V, Oberfield S, Shepherd JA, Kelly A, Winer KK, Kalkwarf HJ, Zemel BS** 2019 Lumbar Spine Bone Mineral Apparent Density in Children: Results From the Bone Mineral Density in Childhood Study. J Clin Endocrinol Metab 104:1283-1292
42. **Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, Mahboubi S, Shepherd JA, Hangartner TN, Frederick MM, Winer KK, Kalkwarf HJ** 2010 Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab 95:1265-1273
43. **Adams JE, Engelke K, Zemel BS, Ward KA** 2014 Quantitative computer tomography in children and adolescents: the 2013 ISCD Pediatric Official Positions. J Clin Densitom 17:258-274
44. **Pui CH, Evans WE** 2013 A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50:185-196

591 **Figure Legends**

592 **Figure 1:** Magnitude of supporting evidence needed to trigger a bone health evaluation
593 in relationship to fracture characteristics

594

595 **Figure 2:** Proposed approach to the diagnosis of osteoporosis in children